StockData
Hyperfine, Inc. logo

Hyperfine, Inc. (HYPR) stock

HYPRNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3021% below fair value
$0.61−0.02 (-3.05%)

Close on Nov 16, 2026Market cap $64.70MP/E –Yield –

Hyperfine r&d expenses

Research and development expenses are spending on new products and technology.

Hyperfine's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.58M, down 24.2% year over year. For fiscal 2025 it was $17.45M, down 22.4% from the year before. The highest annual figure on record is $28.16M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.45M-22.4%
FY2024Dec 31, 2024$22.50M+0.0%
FY2023Dec 31, 2023$22.49M-20.1%
FY2022Dec 31, 2022$28.16M+9.0%
FY2021Dec 31, 2021$25.84M+77.1%
FY2020Dec 31, 2020$14.59M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.87M-14.9%
Q1 FY2026Mar 31, 2026$3.85M-23.7%
Q4 FY2025Dec 31, 2025$3.83M-25.1%
Q3 FY2025Sep 30, 2025$4.05M-31.0%
Q2 FY2025Jun 30, 2025$4.54M-23.8%
Q1 FY2025Mar 31, 2025$5.04M-9.6%
Q4 FY2024Dec 31, 2024$5.11M-14.4%
Q3 FY2024Sep 30, 2024$5.87M+2.2%
Q2 FY2024Jun 30, 2024$5.96M+11.8%
Q1 FY2024Mar 31, 2024$5.57M+2.0%
Q4 FY2023Dec 31, 2023$5.96M+14.2%
Q3 FY2023Sep 30, 2023$5.74M-21.8%
Q2 FY2023Jun 30, 2023$5.33M-26.6%
Q1 FY2023Mar 31, 2023$5.46M-34.5%
Q4 FY2022Dec 31, 2022$5.22M-41.3%
Q3 FY2022Sep 30, 2022$7.34M+14.0%
Q2 FY2022Jun 30, 2022$7.27M+20.3%
Q1 FY2022Mar 31, 2022$8.33M+86.3%
Q4 FY2021Dec 31, 2021$8.89M–
Q3 FY2021Sep 30, 2021$6.44M–
Q2 FY2021Jun 30, 2021$6.04M–
Q1 FY2021Mar 31, 2021$4.47M–

More Hyperfine figures

See a number that looks wrong?